V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330013043 | 330005270 | 1.8 | 61 | Palliative (P) | 2016-07-13 | 2018-03-15 | Doxorubicin + Methotrexate | N | N | 330018777 | BENDAMUSTINE |
| 330013044 | 330005293 | 1.78 | 70 | Curative (C) | 2017-11-26 | 2018-10-31 | CNS HGG Bevacizumab + Irinotecan | 2 | N | 330018990 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330013045 | 330008886 | 0 | 72 | Palliative (P) | 2019-04-12 | 2019-04-12 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | 330019079 | CHOP R + BORTEZOMIB |
| 330013046 | 330005314 | null | 112 | Curative (C) | 2015-11-18 | 2015-12-04 | LOMUSTINE + PROCARBAZINE | N | N | 330019378 | CYTARABINE |
| 330013047 | 330011894 | 1.73 | 80.9 | Palliative (P) | 2014-11-09 | 2014-11-10 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | 2 | N | 330019528 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE |
| 330013049 | 330005336 | 1.73 | 58.6 | Neo-adjuvant (N) | 2015-05-19 | 2015-05-19 | Pazopanib | 02 | N | 330019624 | DOXORUBICIN + IFOSFAMIDE |
| 330013051 | 330005361 | 1.78 | 62.8 | Palliative (P) | 2016-04-02 | 2016-04-02 | FLUDARABINE | N | N | 330019771 | ATG + BUSULFAN + FLUDARABINE |
| 330013052 | 330005366 | 1.67 | null | Palliative (P) | null | 2015-12-11 | CYTARABINE | N | null | 330019784 | VEIP |
| 330013053 | 330005370 | null | 148.9 | Palliative (P) | 2017-07-04 | 2017-07-17 | Ifosfamide | N | N | 330019807 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330013054 | 330010840 | 1.81 | null | Curative (C) | 2014-08-22 | 2015-01-02 | Doxorubicin + Ifosfamide | N | N | 330019906 | ETOPOSIDE + RITUXIMAB |
| 330013055 | 330005407 | 1.72 | 62.6 | Curative (C) | 2015-07-11 | 2015-10-24 | ALL UKALL2011 Consolidation A | N | N | 330020179 | CAPECITABINE + LOMUSTINE |
| 330013056 | 330011907 | 0 | 74.6 | Palliative (P) | 2015-08-25 | 2015-08-26 | Cytarabine intrathecal | N | N | 330020236 | AML18 TRIAL |
| 330013057 | 330005442 | 1.6 | null | Palliative (P) | 2018-11-20 | 2018-11-28 | IMATINIB | N | N | 330020433 | IPO |
| 330013058 | 330008982 | 1.8 | 72.1 | Palliative (P) | 2017-12-14 | 2018-03-13 | IMATINIB | N | N | 330020602 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330013059 | 330005512 | 1.6 | 9.3 | Palliative (P) | 2016-04-01 | 2016-05-10 | CAPECITABINE + VINORELBINE | 02 | N | 330020977 | IMATINIB |
| 330013060 | 330009016 | 1.59 | null | Palliative (P) | 2014-12-04 | 2014-12-20 | MYELOMA XI TRIAL | N | N | 330021093 | GEMCITABINE |
| 330013062 | 330005539 | 0 | 76 | Curative (C) | 2017-10-20 | 2017-10-20 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330021120 | PEMBROLIZUMAB |
| 330013063 | 330005557 | 1.93 | 87.1 | Neo-adjuvant (N) | 2014-09-25 | 2014-09-25 | CHOP R - 21 days | null | N | 330021309 | PEI |
| 330013064 | 330005566 | 1.83 | 54.4 | null | 2016-01-14 | 2016-07-02 | UKALL14- Cons Cycle 2 | Y | N | 330021342 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330013065 | 330005577 | 1.65 | 56.65 | Palliative (P) | 2015-12-31 | 2016-04-04 | CYCLOPHOSPHAMIDE + DOXORUBICIN | 01 | N | 330021428 | CETUXIMAB + CISPLATIN + FU |
| 330013066 | 330011935 | 1.79 | 58 | null | 2016-11-29 | 2017-02-06 | Capecitabine (14 days)+Carboplatin | Y | N | 330021497 | CARBOPLATIN + THIOTEPA + TOPOTECAN |
| 330013067 | 330009053 | 1.8 | null | Palliative (P) | 2014-12-02 | 2014-12-07 | Oxaliplatin + Modified de Gramont | N | N | 330021602 | BENDAMUSTINE |
| 330013068 | 330005598 | 0 | 56.3 | Curative (C) | 2016-11-16 | 2017-02-13 | Cyclophosphamide High Dose | Y | N | 330021653 | IPILIMUMAB |
| 330013069 | 330005614 | null | 69 | Palliative (P) | 2015-01-21 | 2015-01-21 | CHOP R - 21 days | 2 | N | 330021734 | IPO |
| 330013070 | 330005629 | null | null | null | 2018-02-05 | 2018-02-13 | Capecitabine (21days) + Carboplatin | 02 | null | 330022010 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330013071 | 330005638 | null | null | Palliative (P) | 2019-09-16 | 2019-11-24 | DHAP | null | null | 330022152 | BUSULFAN + MELPHALAN |
| 330013072 | 330005643 | 1.7 | null | Palliative (P) | 2018-03-11 | 2018-03-11 | DOXORUBICIN + METHOTREXATE | 2 | N | 330022242 | BENDAMUSTINE |
| 330013073 | 330005677 | 1.6 | 79.9 | Palliative (P) | 2018-08-30 | 2019-01-12 | Triple Intrathecal | N | N | 330022813 | PEMBROLIZUMAB |
| 330013074 | 330005689 | 1.76 | 79.7 | Palliative (P) | 2017-06-24 | 2017-07-26 | Cisplatin + Vinorelbine (IV) | 02 | N | 330022926 | GDP |
| 330013075 | 330013193 | 1.62 | 53 | Palliative (P) | 2017-03-30 | 2017-07-27 | GEMCITABINE | N | null | 330022938 | IDARUBICIN |
| 330013077 | 330009127 | null | 63 | Curative (C) | 2017-11-16 | 2019-02-26 | DHAP | null | N | 330023279 | CISPLATIN + VINORELBINE |
| 330013078 | 330005743 | 0 | 64.5 | Curative (C) | 2019-04-28 | 2019-05-09 | TIP | 2 | N | 330023355 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330013079 | 330005809 | null | 48 | Palliative (P) | 2018-09-13 | 2018-12-27 | Erlotinib | null | null | 330023886 | GEMCITABINE |
| 330013080 | 330005826 | 1.7 | null | Palliative (P) | 2017-04-29 | 2017-07-24 | Cyclophosphamide TBI Allograft | null | null | 330024003 | PEMBROLIZUMAB |
| 330013081 | 330005833 | 0 | 44.4 | Curative (C) | 2018-06-23 | 2018-07-04 | ALL UKALL2011 Maintenance A2 | 02 | N | 330024076 | BENDAMUSTINE |
| 330013082 | 330009180 | null | 65 | null | null | 2018-08-25 | RUXOLITINIB | null | null | 330024126 | IFOSFAMIDE |
| 330013083 | 330009184 | 1.81 | null | Neo-adjuvant (N) | null | 2018-09-15 | Cyclophosphamide High Dose | null | N | 330024179 | BENDAMUSTINE |
| 330013084 | 330005865 | 1.68 | 69 | Curative (C) | 2019-10-02 | 2019-10-02 | LENALIDOMIDE | 02 | null | 330024281 | VIDE |
| 330013085 | 330005883 | 1.83 | 69.6 | Palliative (P) | 2018-03-30 | 2018-03-30 | ATG + Busulfan + Fludarabine | N | N | 330024385 | CETUXIMAB + CISPLATIN + FU |
| 330013087 | 330005910 | null | 104.8 | Palliative (P) | 2015-08-01 | 2015-08-02 | IMMUNOGLOBULIN | 02 | N | 330024541 | BORTEZOMIB + CYTARABINE + RITUXIMAB |
| 330013088 | 330005932 | 1.69 | null | Curative (C) | 2017-05-11 | 2017-07-09 | CNS LGG Irinotecan & Bevacizumab | null | null | 330024744 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330013089 | 330005935 | 1.74 | 50.6 | Adjuvant (A) | 2015-07-21 | 2016-08-26 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 330024769 | TRIPLE INTRATHECAL |
| 330013090 | 330005946 | 1.76 | 20.6 | Palliative (P) | 2016-03-03 | 2016-05-11 | DHAP | 2 | Y | 330024851 | CVP R |
| 330013091 | 330005957 | 1.6 | 68.7 | Curative (C) | 2016-05-26 | 2016-05-26 | Bendamustine +/- Prednisolone | 2 | null | 330024888 | IMATINIB |
| 330013092 | 330005981 | 1.82 | 65.9 | Curative (C) | 2019-10-02 | 2019-10-23 | MAP + MIFAMURTIDE | N | N | 330025052 | FLAG |
| 330013093 | 330005987 | 0 | 52 | Curative (C) | 2017-09-26 | 2017-10-07 | EMA/CO | N | N | 330000507 | DOXORUBICIN + HD MTX |
| 330013094 | 330009272 | 0.96 | 71 | null | 2015-07-04 | 2015-07-10 | INTERFERON | 02 | null | 330004663 | FLAG |
| 330013095 | 330006014 | 0.86 | 56.4 | Curative (C) | 2018-05-14 | 2018-05-16 | IPO | N | null | 330004965 | CISPLATIN + DOX + ETOPOSIDE |
| 330013096 | 330006023 | 1.63 | 99.6 | Palliative (P) | 2015-09-24 | 2016-03-14 | Hydroxycarbamide | N | N | 330006361 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 330013097 | 330006034 | 1.73 | 61.7 | Palliative (P) | 2018-06-18 | 2018-06-22 | Trastuzumab 21 day maintenance | 02 | N | 330007632 | CETUXIMAB + CISPLATIN + FU |